Roche Reports A "Solid" Third Quarter, But Expects Further EU Pricing Pressure
This article was originally published in The Pink Sheet Daily
Roche's sales grew only 2% in the first nine months of 2010, held back by U.S. health care reform and EU price cuts, a decline in Tamiflu sales and adverse currency fluctuations.
You may also be interested in...
FDA's decision to withdraw approval of Roche/Genentech's Avastin for first-line metastatic breast cancer is proving to be an unpopular action, though the ramifications are not yet clear.
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.